FDA Approves Topical Gel Filsuvez for Epidermolysis Bullosa
Summary: The FDA has approved Filsuvez, a birch triterpene topical gel, for treating partial-thickness wounds in patients with Junctional Epidermolysis Bullosa (JEB) and Dystrophic Epidermolysis Bullosa (DEB). Approved for patients aged 6 months and older, this represents the first therapy for JEB-associated wounds in the United States and expands options for those living with EB.
Key Highlights:
- Regulatory milestone: Filsuvez is the first FDA-approved therapy for JEB wounds in the U.S. and the second available treatment for DEB.
- Clinical trial evidence: Approval was based on the EASE Phase 3 trial with 223 participants, which demonstrated improved wound closure compared to control treatment.
- Mechanism & use: The gel, derived from birch bark triterpenes, is applied at each dressing change directly to the wound or to the dressing itself.
- Patient eligibility: Approved for infants, children, and adults 6 months of age and older.
- Safety profile: Reported adverse events were mostly mild to moderate, including wound-related complications and local application site reactions.
Read the full article on Dermatology Times
Keywords:
Filsuvez,
epidermolysis bullosa,
topical therapy,
wound healing,
rare skin disease